PNAS Therapeutics

PNAS Therapeutics is at the forefront of biotechnology research, transforming therapeutics with a next-generation drug delivery platform. Specializing in innovative drug delivery systems (DDS), PNAS Therapeutics utilizes a simple-mixing, self-assembling porous hydrogel without chemical cross-linking, designed for controlled release and long-lasting effects of various active pharmaceutical ingredients (APIs). Their injectable and topical drug-loaded gel offers multiple administration routes, custom formulations with slow-release kinetics, and the ability to mix multiple APIs, aiming to advance treatments across diverse clinical settings.

Located in Oxford, GB, PNAS Therapeutics is dedicated to developing solutions for complex indications, including solid tumors, and is actively seeking partnerships to expand the application of their platform. As a GMP clinical-grade DDS, PNAS Therapeutics is committed to addressing critical challenges in treating conditions like psoriasis and atopic dermatitis by combining multiple therapeutic agents in a novel formulation that enables precise, controlled drug delivery through topical application. With a focus on controlled release drugs, nanogel, and advanced therapeutics, PNAS Therapeutics is setting new standards in the biotechnology sector.

PNAS Therapeutics is shaping the future of targeted, controlled-release therapeutics. The company is focused on expanding the application of its cutting-edge drug delivery systems. More information about PNAS Therapeutics will be completed soon with the support of the company’s management. We invite the manager of PNAS Therapeutics to create a customized and exclusive company showcase and product listing on our platform.